We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bucking bronchos

10 June 2013 By Neil Unmack

The troubled pharma group’s acquisition of Pearl, its second deal in a month, should protect the key respiratory business. New Chief Executive Pascal Soriot is using prudent M&A to flesh out his strategy. Still, the company has a way to go to close its valuation discount.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)